News
SGLT2 Inhibitors, MRA Compared for Diabetic Kidney Disease
Evidence in favor of SGLT2 inhibitors and nonsteroidal mineralocorticoid receptor antagonists for treating patients with diabetic kidney disease is growing.
No significant associations seen for spironolactone with risk for breast, ovarian, bladder, kidney, gastric, esophageal cancers